Nowadays in China, Translational Medicine has become an important national policy in the field of biomedical science. “Suggestions of the Central Committee of the Communist Party of China on the Formulation of the Twelfth Five-Year Plan for National Economic and Social Development” pointed out in the guide book: “With Translational Medicine as the core, vigorously promote biomedical science and technology, strengthen the construction of key disciplines of medicine and health care.

With this in mind, SMG collaborates with ATLATL Innovation Center, the world’s largest Class A biomedical laboratory with on-site CRO/CDMO services to establish Life Science Innovation Park, including industrial leaders, growth companies, as well as startups. As an incubation and acceleration platform, the Life Science Innovation Park helps with projects in the fields of Biotech, Medical Equipment and AI initiated by top experts.

SMG has invested in 3 companies so far, ranging from medical big data with AI capability, to stem cell drugs and anesthesiology drugs. All 3 companies were originated by Peking Union Medical College Hospital (“PUMCH”) experts following an “open innovation” approach, namely, combining with expertise and technologies from outside of PUMCH.